Additional Resources

Societies/Websites

Articles

  1. Lefebvre P, Duh MS, Lafeuille MH, et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J Allergy Clin Immunol. 2015;136:1488-1495.
  2. Nair P, Wenzel S, Rabe K, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448-2458.
  3. Manson S, Brown R, Cerulli A, et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975e994.
  4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800-1809.
  5. McBrien C, Menzies-Gow A. Time to FOCUS on oral corticosteroid stewardship in asthma management (Commentary). Respirology. 2019;24:304-305.
  6. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study. BMJ. 2017;357:j1415.
  7. Choo XN, Pavord I. Morbidity associated with oral corticosteroids in patients with severe asthma. 2016;71:302-304.
  8. Bourdin A, Adcock I, Berger P, et al. How can we minimise the use of regular oral corticosteroids in asthma? Eur Respir Rev. 2020;29:190085.
  9. Fuhlbrigge A, Sharma S. Oral corticosteroid use in asthma: A wolf in sheep’s clothing. J Allergy Clin Immunol Pract. 2021;9:347-348.
  10. Price D, Castro M, Bourdin A, et al. Short-course systemic corticosteroids in asthma: Striking the balance between efficacy and safety. Eur Respir Rev. 2020;29:190151.
  11. Ramsahai JM, Hansbro P, Wark P. Mechanisms and management of asthma exacerbations. Am J Respir Crit Care Med. 2019;199:423-432.
  12. Price D, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: Long-term observational study. J Asthma Allergy. 2018;11:193-204.
  13. Chung L, Upham J, Bardin P, et al. Rational oral corticosteroid use in adult severe asthma: A narrative review. Respirology. 2020;25,161-172.
  14. Tran T, MacLachlan S, Hicks W, et al. Oral corticosteroid treatment patterns of patients in the United States with persistent asthma. J Allerg Clin Immunol Pract. 2021;9:338-346.
  15. Rowe B, Kirkland S, Vandermeer B, et al. Prioritizing systemic corticosteroid treatments to mitigate relapse in adults with acute asthma: A systematic review and network meta-analysis. Acad Emerg Med. 2017;24:371-381.
  16. Bleeker E, Menzies-Gow A, Price D, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020; 201:276-293.
  17. Aljebab F, Choonara I, Conroy S. Systematic review of the toxicity of long-course oral corticosteroids in children. PLoS One. 2017;12:e0170259.
  18. Cataldo D, Louis R, Michils A, et al. Severe asthma: Oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021;58:1-11.
  19. Corren J, Parnes J, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377:936-946.
  20. Bleecker ER, Menzies-Gow A, Price D, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201:276-293.
  21. Castro M, Corren J, Pavord I, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486-2496.
  22. Grant T, Croce E, Matsui E. Asthma and the social determinants of health. Ann All Asthma. 2022;128:5-11.
  23. Rabe K, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378:2475-2485.

Pin It on Pinterest

Directory
Scroll to Top

For optimized Clinical Trial Tracker use, please utilize Chrome or Firefox browsers